Gosuranemab

Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemabbinds to human N-terminaltauresidues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD)[1][2].

[1] Song C, et al. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18. DOI:10.1186/s40035-022-00292-3
[2] Imbimbo BP, et al. A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. Alzheimers Dement. 2022 May;18(5):1008-1037. DOI:10.1002/alz.12453